Aurobindo Pharma Announced Buyback: Check Record, Size and More

On April 6, 2026, Aurobindo Pharma shares are in focus as the company’s board approved a buyback of its equity shares worth ₹800 crore.

Size and Scope of Buyback

According to an exchange filing, the company plans to repurchase up to 54,23,728 fully paid-up equity shares, each with a face value of ₹1. This represents around 0.93% of the company’s total outstanding equity shares. Aurobindo Pharma has set the buyback price at ₹1,475 per share, which is approximately a 10% premium over the stock’s closing price last Thursday. The total size of the buyback has been pegged at ₹800 crore.

The buyback will be conducted through the tender offer route. Under this mechanism, eligible shareholders can tender their shares at the fixed price determined by the company, ensuring uniform pricing for all participants.

Record Date for Eligibility

The company has fixed Friday, April 17, 2026, as the record date to determine shareholder eligibility. This means investors holding shares in their demat accounts as of the market close on April 16 will be eligible to participate in the buyback.

Buybacks are generally seen as a positive signal, indicating management’s confidence in the company’s valuation while also offering shareholders an opportunity to exit at a premium.

Aurobindo Pharma Q3FY26 Earnings Highlights

Aurobindo Pharma reported a steady performance in Q3 FY26, with revenue from operations rising 8.4% year-on-year to ₹8,646 crore, driven largely by strong growth in Europe and the ARV segment. The US formulations business posted a modest 2.2% increase to ₹3,739 crore ($420 million), while Europe formulations recorded a robust 27.4% growth to ₹2,703 crore (€261 million). Revenue from growth markets remained flat at ₹865 crore ($97 million), whereas ARV revenues surged 22.4% to ₹376 crore ($42 million). 

Also Read: Vedanta Share Price in Focus: Recorded Strong Production Across Segments in FY26

Profitability remained healthy, with EBITDA (before R&D) at ₹2,163 crore, reflecting a margin of 25.0%, and EBITDA (before forex and other income) at ₹1,773 crore with a 20.5% margin. The company invested ₹409 crore (4.7% of revenue) in R&D, strengthening its pipeline, and secured final approvals for seven ANDAs from the USFDA. Net profit for the quarter stood at ₹910 crore, including a one-time cost of ₹65 crore due to changes in labour codes. Financially, the company maintained a strong net cash position of $251 million as of December 31, 2025, even after funding the acquisition of Khandelwal Laboratories, and generated free cash flows of $118 million during the quarter.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.